RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma has secured funding from the U.S. government’s BARDA to advance opaganib, a novel treatment for Ebola, following promising results in U.S. Army studies. This collaboration aims to develop opaganib as a mutation-resistant, easily distributed oral therapy, addressing the urgent need for effective treatments amid geopolitical challenges and potential outbreaks. This initiative marks a significant step forward in global health preparedness and biodefense strategies.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
